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The role of glycopeptides in the treatment of intravascular catheter-
related infections
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There is increasing concern over multiresistant staphylococcci in catheter-associated
infections. Local infections due to coagulase-negative staphylococci are usually resolved
by removal of the intravascular catheter. However, if the device should remain for a
certain period of time, e.g. to complete a course of chemotherapy, the antibiotic lock
technique with a glycopeptide should be considered. In case of septic embolism to the
lung caused by a multiresistant Staphylococccus aureus or Enterococcus faecium, systemic
therapy with glycopeptides, streptogramins or linezolid must be employed.
Keywords Glycopeptide therapeutic use, catheter infection, aetiology, prevention and
control
Accepted 24 November 2001
Clin Microbiol Infect 2002; 8: 310–315
B A C K G R O U N D
The increase in the use of venous catheters has
been related to an increase in catheter-associated
infections. Usually the infections are not life threa-
tening and are resolved after removal of the device.
However, patients with intravascular catheters
can be at risk of infectious complications, includ-
ing access-site cellulitis, septic thrombophlebitis,
bloodstream infection, endocarditis and metastatic
infection. Catheter-related bloodstream infections
are associated with increased mortality, morbidity,
length of hospital stay and medical cost. Infection
rates vary greatly, depending on the type of
device, and are highest with central venous cathe-
ters of all types. It is estimated that the fatality rate
of catheter-related bacteraemia is 10–20% [1].
Patients with haematological malignant disease
are often managed with the aid of long-term tun-
nelled central venous catheters, such as Hickman
lines; the security of access provided by these lines
has been a central part of the improvement in
supportive care for patients undergoing intensive
chemotherapy and bone marrow transplantation
over the last few years. The reason for a higher rate
of infection in the central lines of this population
might well be the fact that these patients are
profoundly immunosuppressed and that the lines
remain in position for long periods of time (from
6 months up to 2 years in some patients with short
bowel syndrome).
The most serious form of intravascular catheter-
related infection is suppurative phlebitis and, in
the great central veins, septic thrombosis. With
peripheral intravenous catheters, the infection
has invariably originated from plastic catheters
that have been left in place for prolonged periods,
particularly in burn patients. Septic thrombosis of
the great central veins is characterized by high-
grade septicaemia and, often, septic pulmonary
emboli. In any patient who develops high-grade
cryptogenic sepsis, suppurative thrombophlebitis
or septic thrombosis of the great central vein
should always be suspected.
P A T H O G E N S
The micro-organisms most commonly responsible
for central venous catheter-associated blood-
stream infections are Staphylococcus aureus and
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coagulase-negative staphylococci. Because coagu-
lase-negative staphylococci are ubiquitous on the
skin, their isolation from blood often reflects speci-
men contamination rather than true infection. His-
torically, these micro-organisms were regarded as
relatively avirulent. However, true bloodstream
infections due to coagulase-negative staphylococci
are common. The severity of such infections
depends on the clinical situation. Studies of coa-
gulase-negative staphylococci bacteraemia among
very-low-birth-weight (<1000 g) neonates have
shown that these infections are associated with
increased length of hospital stay and medical cost,
but not with increased mortality. On the other
hand, central venous catheter-associated bactere-
mia due to coagulase-negative staphylococci can
produce life-threatening complications in adults,
such as prosthetic heart valve endocarditis. Noso-
comial bloodstream infections due to coagulase-
negative staphylococci have been shown to be
associated with increased attributable mortality
and cost of hospitalization.
In our institution, a 2200 bed university teaching
hospital, Gram-positive cocci account for 85% of
all pathogens isolated from central venous catheter
tips according to the method described by Maki
et al. [2]. In contrast to previous years, S. aureus is
now the most frequent pathogen (note Table 1),
which might be explained by the fact that micro-
biological examination of catheter tips is now
performed only in cases with clinical signs of
infection, rather than on a routine basis. The inci-
dence of methicillin-resistant S. aureus isolates
in blood cultures is 21%, but from catheter tips
it is 37%. For S. epidermidis isolates the situation is
even worse, 74% are resistant to b-lactams (note
Table 2). Because of this high rate of resistance,
empiric therapy has to include a glycopeptide.
Surprisingly, in India the most common pathogens
isolated from central venous catheters are Gram-
negative organisms [3].
T H E R A P Y
Line infections can be difficult to eradicate, often
requiring removal of the line and its subsequent
replacement. There are certain circumstances,
however, where removal of a line is inappropriate.
For example, during, or just before, the final che-
motherapy course, there is little point in replacing
a line when only 2 or 3 weeks of further care is
needed. Palliative care necessitates long lines for
the continuous administration of opiate analgesics
and other supportive care. Therefore it is impor-
tant to maintain these lines and to interfere with
these patients as little as possible.
Central venous catheters in patients with fever
and mild to moderate disease should not routinely
be removed. However, central venous catheters
should be removed and sent to the microbiology
laboratory if the patient has severe disease or
erythema overlying the catheter exit site, puru-
lence at the catheter exit site, or clinical signs of
unexplained sepsis. If the blood culture results are
positive, or the central venous catheter is
exchanged over a guide wire and has significant
colonization by quantitative or semiquantitative
cultures, the catheter should be removed and a
new catheter should be placed at a new site.
In patients with S. aureus bacteremia, a possible
endocarditis should be excluded. If available,
transoesophageal echocardiography should be
used to rule out vegetations in patients with
Staphylococcus aureus catheter-related bloodstream
infection. A transoesophageal echocardiogram
Table 1 Micro-organisms isolated from central venous
catheter tips at the University Hospital Vienna, 1998–2000
n %
Staphylococcus aureus 168 50.1
Staphylococcus epidermidis 105 31.3
Candida albicans 12 3.6
Pseudomonas aeruginosa 11 3.3
Corynebacterium spp. 7 2.1
Other Gram-positive cocci 14 4.5
Other Gram-negative rods 17 5.1
Total 334 100.0
Table 2 Antimicrobial sensitivity of staphylococci isolated
from central venous catheter tips vs. blood cultures at the
University Hospital Vienna, 1998–2000
Catheter tips Blood cultures
S. aur.
(n¼ 168)
S. epid.
(n¼ 105)
S. aur.
(n¼ 360)
S. epid.
(n¼ 868)
Oxacillin 63% 31% 79% 26%
Clindamycin 61% 28% 77% 35%
Gentamicin 60% 44% 77% 45%
Ciprofloxacin 53% 29% 73% 44%
Vancomycin 100% 100% 100% 100%
Teicoplanin 100% 100% 100% 100%
S. aur., Staphylococcus aureus; S. epid., Staphylococcus
epidermidis.
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should also be performed in bacteraemia due to
coagulase-negative staphylococci in patients with
predisposing cardiac risk factors such as a pros-
thetic valve. The ideal time to perform transoeso-
phageal echocardiography in this setting has not
been defined. However, if there is persistent bac-
teremia or fungemia, or a lack of clinical improve-
ment, especially if more than 3 days have passed
since catheter withdrawal and initiation of appro-
priate antimicrobial therapy has not been effective;
then an aggressive work-up for septic thrombosis,
infective endocarditis and other metastatic infec-
tions should be ensured.
Antibiotic therapy for catheter-related infection
is often initiated empirically. The initial choice of
antibiotics will depend on the severity of the
patient’s clinical disease, the risk factors for infec-
tion, and the pathogens likely to be associated with
the specific intravascular device. Although there
are no data that support the use of specific empiric
antibiotic therapy for device-related bloodstream
infection, a glycopeptide is usually recommended
in hospitals with an increased incidence of methi-
cillin-resistant staphylococci. This is warranted
because of its activity against coagulase-negative
staphylococci and S. aureus. In the absence of
methicillin-resistant S. aureus, penicillinase-resis-
tant penicillins, such as Flucloxacillin or Oxacillin,
should be used, unless the patient is allergic to
penicillins.
S Y S T E M I C T H E R A P Y W I T H
G L Y C O P E P T I D E S
Two glycopeptides, vancomycin and teicoplanin,
are available in Europe. Vancomycin has been
known since 1956 and has been used extensively
parenterally for systemic staphylococcal infec-
tions, including those caused by methicillin-resis-
tant strains. It has been used orally on a large scale
for Clostridium difficile-associated colitis. The major
drawbacks of vancomycin use were histamine-
induced reactions, thrombocytopenia and ototoxi-
city.
Teicoplanin has potential for use as an alterna-
tive to vancomycin in the treatment of Gram-posi-
tive bacterial infections, especially those caused by
methicillin-resistant pathogens. Similar to vanco-
mycin in structure, mechanism of action, and in
vitro activity, teicoplanin is, however, highly pro-
tein bound (>90%) and has a much longer half-life
in serum than vancomycin (>50 h). Both glycopep-
tides are poorly bactericidal against Staphylococcus
hemolyticus. The activity of teicoplanin against S.
epidermidis might be slightly inferior to that of
vancomycin. Teicoplanin shows less vestibular
toxicity and ototoxicity than vancomycin and
has the advantage that it can be given intramus-
cularly as well as intravenously. There is sufficient
evidence that teicoplanin is as effective as vanco-
mycin and that teicoplanin has a safety profile,
which makes it suitable for both inpatient and
outpatient administration.
For vancomycin the recommended dose for
catheter-related infections is 15 mg/kg every
12 h with a target trough level of 5–10 mg/L. For
teicoplanin a loading regimen of 6 mg/kg every
12 h for three doses is recommended, followed by
6 mg/kg/day. Alternatively a single dose of 18–
20 mg/kg infused over a 30-min period can be
given, followed by a daily dose of 6 mg/kg.
Of 25 patients with bacteremia related to right
atrial catheters, five (20%) who were switched
from vancomycin after allergic responses were
cured, as were 12 (60%) of 20 patients given tei-
coplanin from the start of the therapy [4]. Staphy-
lococcus hemolyticus was responsible for three
(38%) of the eight treatment failures. Four patients
switched to vancomycin were later cured. Teico-
planin was effective in all 19 patients with Hick-
man catheter-associated staphylococcal infection
[5]. Teicoplanin in combination with ciprofloxacin
has been used successfully for outpatient treat-
ment of catheter infections in leukemic patients
[6]. Randomized trials show no difference between
vancomycin and teicoplanin in the treatment of
vascular access bacteraemia. A double-blind com-
parison of teicoplanin and vancomycin conducted
by Gilbert et al. [7] included nine patients with
staphylococcal bacteremia related to catheters. In
concert with catheter removal, all were cured. An
unpublished blinded US trial (102–009, data on
file) compared teicoplanin, 6 mg/kg/day, with
vancomycin, 15 mg/kg/day, in the treatment of
vascular access-associated bacteremia. Of 244
patients, only 124 (50.8%) were thought assessable,
but the clinical success rate was 80.0% (48/60
patients) for teicoplanin and 79.7% (51/64
patients) for vancomycin. Eradication rates were
77.4% and 79.3% (24/31 vs. 23/29 patients, respec-
tively) for S. aureus and 89.7% and 88.6% (26/29 vs.
31/35, respectively) for coagulase-negative sta-
phylococci. Smith et al. [8] compared teicoplanin
and vancomycin in 72 episodes of Hickman
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catheter-associated infection in neutropenic
patients and found response rates of 69% and
80%, respectively. Of those with tunnel infections,
all four given vancomycin failed, compared to
three (60%) of five given teicoplanin. As with
vancomycin, doubling the above-mentioned doses
might be necessary in severe staphylococcal infec-
tions. In a study conducted by Gilbert et al. [7] the
recommended dose of 6 mg/kg/24 h of teicopla-
nin was regarded as too low. In our institution the
target trough level for vancomycin is 10–20 mg/L
and for teicoplanin it is 20–30 mg/L, especially in
intravascular catheter-related infections such as
septic thrombophlebitis and endocarditis.
A N T I B I O T I C L O C K T H E R A P Y
One reason for treatment failure with regard to
vascular catheter infections is the inability of most
antibiotics to kill micro-organisms growing in a
biofilm at therapeutically achievable concentra-
tions. Recent studies have demonstrated that anti-
biotic concentrations must be 100–1000 times
greater to kill sessile bacteria than to kill plank-
tonic bacteria. A potential solution to this problem
is based on the fact that the majorities of infections
in tunnelled catheters originate in the catheter hub
and spread to the catheter lumen. This fact has
prompted several investigators to try filling the
catheter lumen with pharmacological concentra-
tions of antibiotics and leaving them there for
hours or days, the so-called ‘antibiotic lock’ tech-
nique.
Although the duration of antibiotic lock therapy
has varied among different studies, it is most
frequently 2 weeks. The lowest salvage rate report-
ed was with a mean of 8 days of therapy. Vanco-
mycin and teicoplanin remain stable when kept in
heparin or saline solutions at room temperature
for days; this allows for antibiotic lock therapy
with heparin, overnight or longer if indicated.
Catheter life was prolonged by a mean of 132 days
after completion of treatment with teicoplanin. A
review of the antibiotic lock technique is given by
Carratala´ in this issue [9].
D U R A T I O N O F T H E R A P Y
There are no compelling data to support specific
recommendations regarding the duration of ther-
apy for device-related infections. Patients with
catheter-related bacteremia should be separated
into those with complicated infections, in which
there is septic thrombosis, endocarditis, osteomye-
litis, or possible metastatic seeding, and those with
uncomplicated bacteremia, in which there is no
evidence of such complications. If there is a
prompt response to initial antibiotic therapy, most
patients who are not immunocompromised, with-
out underlying valvular heart disease or an intra-
vascular prosthetic device, should receive 10–
14 days of antimicrobial therapy for pathogens
other than coagulase-negative staphylococci. A
prolonged course of antibiotic therapy (duration,
4–6 weeks) should be considered if there is persis-
tent bacteraemia or fungemia after catheter
removal or if there is evidence of endocarditis or
septic thrombosis. Six to eight weeks of therapy
should be considered for the treatment of osteo-
myelitis.
F O U R C A S E E X A M P L E S O F T H E R A P Y
W I T H G L Y C O P E P T I D E S I N
I N T R A V A S C U L A R C A T H E T E R -
R E L A T E D I N F E C T I O N S
Case 1
A 62-year-old-woman with short bowel syndrome
received parenteral nutrition via a recently
implanted port-a-cath. After a period of 25 weeks
she developed a 40 8C temperature. Staphylococcus
lugdunensis was isolated from aspiration material
from the port and peripheral blood cultures.
Gastroenterologists refused to remove the infected
port. Systemic treatment with teicoplanin, 12 mg/
kg/day, was started. Trough levels of teicoplanin
were maintained above 20 mg/L. After 2 days the
patient was afebrile, blood cultures remained
negative, and levels of C-reactive protein became
normal. Therapy was discontinued after 2 weeks.
The port could be used for parenteral nutrition for
another 2 months.
This case shows that removal of the infected
device is not always necessary. Teicoplanin is a
good choice in this indication, probably because
of bonding of teicoplanin bonds to the catheter
material.
Case 2
A 25-year-old patient with a bicuspid aortic valve
and asymptomatic coarctation of the aorta
was admitted with diarrhoea and fever. He
received amoxicillin/clavulanic acid for suspected
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salmonellosis via a peripheral venous catheter. No
pathogen could be isolated from stool and blood.
After a treatment period of 7 days he developed
high fever associated with multi-organ failure. A
methicillin-resistant S. aureus was grown from
multiple blood cultures. Transoesophageal echo-
cardiography revealed a destructive endocarditis
of the aortic valve. Treatment with vancomycin
was started but withdrawn because of systemic
intolerability. The patient received teicoplanin,
15–20 mg/kg/day, to achieve a trough level
between 20 and 30 mg/L. His condition improved
markedly within 10 days, blood cultures became
negative. Nevertheless, valve replacement was
necessary after 2 months, and there were no
further complications. The explanted aortic valve
was sterile.
This case illustrates a serious complication of
peripheral vein catheters in a patient with a pre-
disposing factor for endocarditis, namely a bicus-
pid aortic value.
Case 3
A ‘perm cath’ was implanted in a 45-year-old
woman with chronic renal failure. After 10 days
she developed fever up to 38 8C. A methicillin-
resistant S. epidermidis was isolated from periph-
eral and catheter blood cultures. Therefore, she
received vancomycin 500 mg after each haemodia-
lysis session, resulting in a trough level of 8 mg/L.
Initially the fever went down but it recurred after
2 weeks and S. epidermidis was again present in
several consecutive blood cultures. The dose of
vancomycin after dialysis was increased to
1000 mg, resulting in trough levels of 16 mg/L.
After a treatment period of 10 days the patient
recovered and the ‘perm cath’ could be maintained
for a period of 6 weeks. No side-effects with regard
to platelet count or ototoxicity occurred.
This case shows that the recommended trough
level of vancomycin might be too low – at least in
catheter-associated infection with Staphylococcus
epidermidis. The antibiotic lock technique might
have resulted in earlier cure.
Case 4
A 40-year-old man with arteriovenous conduction
impairment following surgery for an atrial septal
defect, had received a total of four pacemakers
since the age of 12 years. Four electrodes were
present in the vena cava superior. Because of with
a trauma to the left shoulder, a central venous
catheter was implanted, resulting in a septic state
after 2 weeks. S. aureus was demonstrated in blood
cultures. Teicoplanin treatment was started and
continued on an outpatient basis for 6 weeks after
recovery from septicaemia. During the following
2 years the patient had recurrent bacteremia due to
Staphylococcus aureus, always responding to 2–
3 weeks of outpatient treatment courses with tei-
coplanin. Recently, the patient was admitted
because of a new episode of severe septicaemia,
again caused by S. aureus. Echocardiography
revealed endocarditis of the tricuspid valve asso-
ciated with thrombosis of the vena cava superior.
Again, treatment with teicoplanin was started and
the patient recovered completely from his septic
state within 2 weeks. The electrodes were finally
removed by thoracotomy after 4 weeks. Cultures
from one of the electrodes grew a teicoplanin-
sensitive S. aureus, which was identical to the
previous strains recovered from blood cultures.
After implantation of an epicardiac pacemaker
no further episodes of S. aureus bacteremia
recurred.
This last example shows that in the presence of a
foreign body, the eradication of infection is often
not possible, requiring the removal of the infected
device in spite of the apparent clinical cure of the
patient with an antibiotic.
S U M M A R Y
Central venous catheters have a pivotal role in the
management of critically ill and hemato-oncologi-
cal patients. The increase in the use of indwelling
intravenous catheters has been associated with a
parallel increase in the incidence of infections
caused by S. epidermidis and S. aureus. Because
of the high incidence of resistance to methicillin,
vancomycin and teicoplanin have a special role in
the treatment of catheter-associated infections. At
the University Hospital of Vienna methicillin resis-
tance in S. aureus (n¼ 168) and S. epidermidis
(n¼ 105) isolated from central venous catheter tips
in the period 1998–2000 was 37% and 69%, respec-
tively. These data indicate the requirement for
empiric use of a glycopeptide. Comparative stu-
dies have shown teicoplanin and vancomycin to be
equally effective and to be well tolerated. The
once-daily administration of teicoplanin enables
treatment on an outpatient basis.
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